SCHEMBL10044898

SCHEMBL10044898

COC(=O)c1c(O)c2c(OC)cccc2n(C)c1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.58
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 2/20 0.46
TSHR P16473 1/20 0.45
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
POLB P06746 3/20 0.44
PABPC1 P11940 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
BRPF1 P55201 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
MAP3K5 Q99683 1/20 0.41
MAPT P10636 3/20 0.41
ALOX15 P16050 2/20 0.41
RECQL P46063 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6997306 0.88 HDAC4 (0.59) HDAC4ALDH1A1KDM4ETSHRMEN1
SCHEMBL30182558 0.88 HDAC4 (0.59) HDAC4ALDH1A1KDM4ETSHRMEN1
SCHEMBL6996658 0.87 ALDH1A1 (0.64) HDAC4ALDH1A1KDM4EMEN1KMT2A
SCHEMBL7826321 0.86 HDAC4 (0.58) HDAC4ALDH1A1KDM4ETSHRMEN1
SCHEMBL39437 0.84 EGFR (0.48) HDAC4ALDH1A1KDM4EMEN1KMT2A
SCHEMBL11983226 0.84 EGFR (0.56) HDAC4ALDH1A1KDM4ETSHRMEN1
SCHEMBL10044897 0.83 KDM4E (0.51) HDAC4ALDH1A1KDM4EMEN1KMT2A
SCHEMBL15154436 0.82 HDAC4 (0.54) HDAC4ALDH1A1TSHRMEN1KMT2A
SCHEMBL15164761 0.82 AHR (0.55) HDAC4ALDH1A1KDM4EMEN1KMT2A
SCHEMBL12254514 0.82 HIF1A (0.52) HDAC4KDM4ETSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240277693-A1 A PHARMACEUTICAL PRODUCT CONTAINING TASQUINIMOD AND A METHOD FOR ASSESSING THE PURITY OF SAID PRODUCT ACTIVE BIOTECH AB (SE) 2024-08-22 US disclosed
EP-4363404-A1 A PHARMACEUTICAL PRODUCT CONTAINING TASQUINIMOD AND A METHOD FOR ASSESSING THE PURITY OF SAID PRODUCT Active Biotech AB (SE) 2024-05-08 EP disclosed
CN-117500790-A Pharmaceutical product containing taquinimod and method for evaluating purity of said product 活跃生物技术有限公司 2024-02-02 CN disclosed
WO-2023275248-A1 A PHARMACEUTICAL PRODUCT CONTAINING TASQUINIMOD AND A METHOD FOR ASSESSING THE PURITY OF SAID PRODUCT ACTIVE BIOTECH AB (SE) 2023-01-05 WO disclosed
EP-2723340-B1 DEUTERIUM-ENRICHED 4-HYDROXY-5-METHOXY-N,1-DIMETHYL-2-OXO-N-[(4-TRIFLUORO-METHYL)PHENYL]-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE ACTIVE BIOTECH AB (SE) 2017-11-22 EP disclosed
US-9216956-B2 Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide ACTIVE BIOTECH AB (SE) 2015-12-22 US disclosed
EP-2590949-B1 METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES ACTIVE BIOTECH AB (SE) 2015-11-25 EP disclosed
EP-2590949-B1 METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES ACTIVE BIOTECH AB (SE) 2015-11-25 EP disclosed
US-8871936-B2 Method for manufacturing of quinoline-3-carboxamides ACTIVE BIOTECH AB (SE) 2014-10-28 US disclosed
US-8871936-B2 Method for manufacturing of quinoline-3-carboxamides ACTIVE BIOTECH AB (SE) 2014-10-28 US disclosed
US-8871936-B2 Method for manufacturing of quinoline-3-carboxamides ACTIVE BIOTECH AB (SE) 2014-10-28 US disclosed
US-20140112946-A1 DEUTERIUM-ENRICHED 4-HYDROXY-5-METHOXY-N,1-DIMETHYL-2-OXO-N-[(4-TRIFLUORO-METHYL)PHENYL]-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE ACTIVE BIOTECH AB (SE) 2014-04-24 US disclosed
US-20130109860-A1 METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES ACTIVE BIOTECH AB (SE) 2013-05-02 US disclosed
US-20130109860-A1 METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES ACTIVE BIOTECH AB (SE) 2013-05-02 US disclosed
US-20130109860-A1 METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES ACTIVE BIOTECH AB (SE) 2013-05-02 US disclosed
EP-2537517-A1 Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide Active Biotech AB (SE) 2012-12-26 EP disclosed
WO-2012004338-A1 METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES ACTIVE BIOTECH AB (SE) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109860-A1 METHOD FOR MANUFACTURING OF QUINOLINE-3-CARBOXAMIDES ADH1A, ADH5, ADH1C HDAC4 2021/4885ALDH1A1 7/4885KDM4E 1451/4885
US-20140112946-A1 DEUTERIUM-ENRICHED 4-HYDROXY-5-METHOXY-N,1-DIMETHYL-2-OXO-N-[(4-TRIFLUORO-METHYL)PHENYL]-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE H1-5, MALT1, H1-4 HDAC4 249/4885ALDH1A1 1885/4885KDM4E 154/4885
US-20240277693-A1 A PHARMACEUTICAL PRODUCT CONTAINING TASQUINIMOD AND A METHOD FOR ASSESSING THE PURITY OF SAID PRODUCT TPMT, TLR7, MYD88 HDAC4 1044/4885ALDH1A1 1211/4885KDM4E 484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.